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Dengue virus (DV†) is one of the most important vector-borne diseases in the world. It
causes a disease that manifests as a spectrum of clinical symptoms, including dengue he-
morrhagic fever. DV is proficient at diverting the immune system to facilitate transmission
through its vector host, Aedes spp. mosquito. Similar to other vector-borne parasites,
dengue may also require a second structural form, a virus of alternative morphology (VAM),
to complete its life cycle. DV can replicate to high copy numbers in patient plasma, but no
classical viral particles can be detected by ultra-structural microscopy analysis. A VAM ap-
pearing as a microparticle has been recapitulated with in vitro cell lines Meg01 and K562,
close relatives to the cells harboring dengue virus in vivo. VAMs are likely to contribute to
the high viremia levels observed in dengue patients. This review discusses the possible ex-
istence of a VAM in the DV life cycle.
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Dengue virus (DV) is one of the most
important vector-borne diseases today, con-
tractible by the bite of a DV-infected female
Aedes spp. mosquito [1]. It causes 500,000
hospitalizations a year and threatens to in-
fect two-fifths of the world’s population.
These statistics are only likely to increase
with the lack of success at controlling trans-
mission  and  preventing  outbreaks.  DV
causes a disease that manifests as a spectrum
of clinical presentations, with initial symp-
toms appearing similar to other common
febrile illnesses such as influenza. The most
common form is severe fever, myalgia, and
thrombocytopenia (dengue fever, DF), and
the less common forms of disease are hem-
orrhaging (dengue hemorrhagic fever, DHF)
or  DHF  with  plasma  leakage  leading  to
shock and multi-organ failure (dengue shock
syndrome, DSS). Although the acute DF is a
self-limiting infection, a subset of DF pa-
tients  rapidly  progress  into  a  secondary
phase, known as DHF/DSS. This life-threat-
ening condition often occurs after the clear-
ance of viremia and is generally thought to
be an immune-mediated disease. Adequate
and timely diagnosis is a major challenge to
physicians, considering the delay in patient
hospital enrollment and the variety and non-
specificity of the clinical symptoms. Cur-
rently, there is no preventive or therapeutic
treatment available for dengue. Rehydration
therapy and palliative care with close mon-
itoring  are  the  only  approved  practices
known to reduce mortality and improve pa-
tient outcomes.
DV was once a clinically significant
pathogen in the United States, before the
mosquito vector was nearly eradicated in the
Americas by spraying with DDT. However,
dengue was not eliminated in the rest of the
world. With increased human travel, un-
planned urban development, global warm-
ing, lack of effective vector control, and the
expansion of the Aedes spp. niche, dengue
has penetrated to almost every corner of the
world [2]. It is perceivable that dengue will
infiltrate back into the United States, since
effective mosquito control measures are still
in their infancy and the population is im-
munologically na￯ve. The increasing inci-
dence of dengue disease worldwide and its
escalating costs to the health care system has
heightened public awareness and led to an
augmentation in activity developing vac-
cines and drugs. Medical interventions that
can prevent and alleviate dengue symptoms
are greatly needed, but promising candidates
will not be likely without a clearer under-
standing of dengue virus life cycle. 
Much  has  been  established  in  the
dengue virus field, such as the clinical pro-
gression of disease in dengue patients and
the virus structure and life cycle in vitro.
However, the structure and the life cycle of
the virus in human plasma or the form that
enters the insect proboscis has remained un-
known since it has never been recorded thus
far. Our observations with patient plasma
and megakaryocyte erythrocyte progenitor
(MEP) cell lines, Meg01 and K562, support
the idea that DV can take on a different
form, residing in host-derived microparticles
(MPs). In this review, we will discuss the
possibility of a virus of alternative morphol-
ogy (VAM) that may allow dengue to divert
the immune system, comparable to other
vector-borne diseases such as malaria. This
implies that antibodies to Vero-derived virus
may not be a good predictor for protection
against dengue or an index for virus neu-
tralization within the human host, and an al-
ternate method should be used to evaluate
efficacy of drugs and vaccines.
Dengue VIRuS’S pRopagatIon
anD StRuctuRe in vivo anD in
vitro
Various in vitro [3] as well as numerous
primary cell lineages have been studied for
their  relative  permissiveness  for  dengue
virus  infection,  including  endothelial,  fi-
broblast, myeloid-derived, and lymphocytic
cells [3-11]. Due to difficulties and incon-
sistencies in identifying the cell lineages re-
sponsible for dengue viremia at the acute
stage in vivo and the low infectivity of the
primary phagocytic cells [12], the hypothe-
sis  of  antibody-dependent  enhancement
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ADE hypothesis attempts to explain why
disease is much more severe in people upon
re-infection with heterologous dengue viral
serotypes. The assumption is that the anti-
body made during the first infection does not
have a high enough affinity to neutralize the
secondary heterologous serotype; this par-
tial cross-reactive (or sub-neutralizing) an-
tibody may enhance the virus opsonization
and  uptake  by  Fc-bearing  cells  such  as
monocytes and macrophages, leading to in-
creased  virus  production.  However,  con-
flicting reports with results obtained in vitro
abound in the literature on the immune-me-
diated pathogenesis; some reports support
the view [14-16], while others dismiss the
theory [3,17-23]. It is still disputed which
cells take up dengue virus in vivo, as well as
the receptors required for virus entry. Con-
sequently, much of the research on dengue
virus biology has been performed with con-
venient in vitro cell lines.
The genome of DV is a positive-sense
RNA strand of about 11 kilobases [24,25].
The viral RNA has the same polarity as
mRNA, and if the viral RNA can be deliv-
ered into a cell’s cytoplasm through biolog-
ically  active  vesicles,  translation  and
genome synthesis can occur and induce in-
fection without the need of virus-encoded
proteins  [26].  From  this  sequence,  a
polyprotein is translated and becomes pro-
teolytically cleaved into at least 10 known
viral protein subunits: three structural pro-
teins  designated  capsid  (C),  premem-
brane/membrane  (PrM/M),  envelope  (E),
and seven nonstructural proteins (NS) [27].
The order of the gene products encoded by
the  genome  is  C-PrM/M-E-NS1-NS2A-
NS2B-NS3-NS4A-NS4B-NS5 [28]. 
The most investigated DV structures
(intact virion and the envelope protein) were
produced in Vero or insect cell lines such as
C6/36 and Schneider 2 [24,29,30]. These
classical virus particles are known to have
three dominant stages: immature, mature,
and mature fusion-ready (or mosaic parti-
cles) [24,31]. The immature intermediate
structure has a rough surface consisting of
60 spikes of E/PrM dimers; further process-
ing (low pH alterations in combination with
cleavage by cellular furin protease) results
in the mature cleaved form, which is smaller
with a smooth outer surface made up of 90
E dimers. In the third classical viral form,
the E protein rearranges into a homotrimer
conformation, which is capable of fusion
with the host lipid bilayer. It is assumed that
the mature virion is the dominant form con-
tained in insect saliva because it is the most
infectious in cell culture; however, the input
virus acquired by mosquitoes after blood
meal has never been imaged. 
Less information is known about the
dengue virus particles formed in mammalian
cells. They are presumed to be identical to
the insect cell structural form with likely
variation in post-translational modifications
[32]. To the best of our knowledge, crystal-
lography has not been performed with mam-
malian-derived  virus  to  confirm  this.
Electron microscopy (EM) techniques have
been the most frequently employed methods
to visualize virus structures from other cell
types. Dengue virus has been cultured in
quite a high number of cell lines, totaling
more than 30 [33]. As of yet, EM pictures of
progeny virions have only been obtained
from a few of these, mainly insect and kid-
ney cell lines [34-37]. Only Barth et al. has
investigated  the  structure  of  virus  from
human serum. These low-resolution images
depict “fuzzy” virions, suggesting the pres-
ence of a virus of alternative morphology
(VAM) in vivo [38,39]. 
VIRuSeS of alteRnatIVe 
MoRphology (VaMs)
Heterogeneous populations of dengue
virus particles have been observed for more
than four decades [40-42]. The types found
have been highly dependent on the cell type
examined. The term “viruses of alternative
morphology  (VAMs)”  is  defined  as  any
structures or conformations deviated from
the classical dengue virus particle. Thus, in
the old literature, VAMs are referred to as
the rapidly and slowly sedimenting hemag-
glutinin antigens (RHA and SHA), which
were virus forms fractionated from mouse
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ameter, increased in frequency with pro-
cessing, and appeared to be noninfectious
[40,41]. This particular form is likely to be
an artifact from replication in an abnormal
organism and may help explain why mouse-
derived  virus  is  attenuated  in  humans
[45,46]. RHA is the 50nm classical virion,
capable of infecting indicator cells such as
Vero [40]. The VAMs manufactured in other
cell lines display different characteristics. A
fuzzy virus morphology has been noted in a
few sources [19,39]. This morphology has
been viewed to be an apoptotic particle in
the virus-infected monocytic cell and is not
infectious, suggesting it is SHA [19]. Addi-
tionally, the virus derived from the mosquito
C6/36 cell line has a 30nm diameter and is
deficient in capsid protein but yet still in-
fectious [47].
All of these VAMs may not be relevant
in vivo. Viruses can easily evolve to repli-
cate in cell lines that they cannot normally
infect;  this  has  been  countlessly  demon-
strated in the past with vaccine develop-
ment.  Viruses  have  been  propagated  in
alternative organisms or cell types to pro-
duce an attenuated strain [48]. This strategy
is thought to force the virus to evolve toward
better replication in another cell type, mak-
ing them less capable of infecting the ap-
propriate host cells or diverting their ability
to counter the immune system when placed
back into man. Viruses can also be over-
propagated through cell culture, potentially
replicating too well in these cells, and fail at
preventing disease in experimentation [49].
Likewise,  over-adaptation  and  good
replication of viruses in these in vitro cell
lines often leads to the development of char-
acteristics that are irrelevant in vivo. In the
absence of the appropriate receptor synapse,
viruses can still find a way inside the cell.
The  virus  receptor  may  bind  weakly  to
abundantly expressed host proteins, leading
to clustering and high avidity interactions.
When placed into cell culture at high con-
centrations for prolonged periods of time,
these weak interactions eventually lead to
the right conditions that favor fusion for a
portion of virions. One example of a virus
entry mechanism brought about by cell cul-
ture adaptation is dengue virus interactions
with heparan sulfate [50-52]. Much attention
was spent investigating this feature of the
DV life cycle, but it was later determined in
vaccine preclinical trials that DV with high
affinity to this receptor was actually attenu-
ated in macaques [53]. This emphasizes the
importance of studying virus entry in the
most appropriate cell types, the ones they
naturally infect. This should improve the
chances of investigating mechanisms still
relevant in vivo. For example, in vitro, the
domain III of the DV E protein, a drug tar-
get, is predominantly exposed on the mature
virus and can easily be bound by rodent-de-
rived neutralizing antibodies to prevent fu-
sion [54]. However, work with human serum
has demonstrated the lack of antibodies spe-
cific to these epitopes, suggesting that this
structure is specific to in vitro virus and is
not present in humans [55,56]. One expla-
nation for the absence of domain III anti-
bodies  may  be  masking  by  heavy
glycosylation, suggested by the fuzzy virion
morphology occasionally noted in some in-
vestigations [19,38,39]. Another explanation
may be that the structural conformation is
completely different. The literature indicates
that virus-like particles differing from the
classical virion can be observed in dengue-
infected  human  and  rhesus  macaque
platelets [57,58]. Human serum also pos-
sesses the capacity to neutralize in vitro cul-
tured  DV,  suggesting  that  neutralization
antibodies are present but bind other epi-
topes [59]. 
Surprisingly  there  are  practically  no
published investigations on the DV mor-
phology in vivo, despite the high levels of
viremia in patients. It is presumed that many
researchers have tried but failed to detect
classical dengue virions either in plasma,
serum, or peripheral blood mononuclear cells
[60]. One reason for this failure may be be-
cause the investigators were looking for the
structure crystallized from insect cell lines.
Another  reason  may  be  isolation  of  the
wrong  blood  components.  Only  recently
were virus particles depicted in human and
rhesus macaque platelets [57,58]. Interest-
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replication [61]. Careful inspection of the
Vero-derived and platelet-derived classical
virions reveal that these particles are slightly
different from each other (Figure 1). They
both have diameters in the 40-50nm range,
but the platelet-derived classical virus form
is more heterogeneous (Figure 1B and C).
Some platelet vesicles contain fuzzy debris,
potentially a type of VAM (Figure 1B and
C). Also there is an interesting formation
blebbing off the platelet (Figure 1C). This
microparticle  (MP)  appears  to  be  mostly
empty, containing a vesicle (a structure also
seen in DV-infected Vero cells) that also
could be considered a VAM (Figure 1A and
C). It has the appearance of a virus-induced
vesicle, which has also been noted in other
EM studies [36]. The function of these virus-
induced vesicles is unknown, but we hy-
pothesize them to be a possible alternative
DV RNA-containing virion that may allow
the virus to escape aspects of the immune
system. We suggest that MPs may play a role
in dengue virus infection and transmission,
potentially by shielding DV from aspects of
the immune system. Dengue-specific anti-
bodies often cross-react with self-proteins,
suggesting that VAM can hide from the neu-
tralizing antibody response [62].
MIcRopaRtIcleS (MpS) anD theIR
InVolVeMent In InfectIonS
Microparticles (MPs), the vehicles of
cell-cell  communication,  often  contain
mRNA,  miRNA,  and  proteases  [63-67].
These vesicles can bleb off the plasma mem-
brane or form within multivesicular body
(MVB) compartments, which then fuse at
the cell surface, releasing their microvesic-
ular contents. Many review articles have dis-
cussed  MP  involvement  in  various
biological phenomenon [68-73]. There are a
few investigations that have observed trans-
mission of virus through MPs [74,75]. One
notable example of this is hepatitis C virus,
a close relative to DV. Other microbes from
various domains of life have been noted for
their ability to alter MP content and promote
their  transmission  [76-80].  DV,  as  men-
tioned earlier, only requires the presence of
its genome to initiate an infection. If its tran-
scripts or genome have the capacity to be
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figure 1. transmission eM images of DV2-infected Vero cells and dengue patient
platelets. Vero cells were infected with a multiplicity of infection equal to 5 for 18 hours,
and samples were prepared as previously described [58]. Human platelets were isolated
from acute dengue patients via Optiprep, and platelets were fixed with 4 percent glu-
taraldehyde in PBS. Samples were washed and fixed with 2 percent osmium tetraoxide
and stained with uranyl acetate. Stained specimens were infiltrated with propylene oxide
and epoxy resin, embedded in a polypropylene capsule and visualized with a Hitachi
Transmission Electron Microscope. a) Dengue classical virions can be seen in endocytic
vesicles of infected Vero cells. B and c) Dengue viral particles inside platelet vesicles iso-
lated from two acute dengue patients. Red arrows indicate viral- particles inside virus-in-
duced vesicle structure.packaged  into  microvesicles,  like  host
mRNA and miRNAs, they may easily get
distributed broadly throughout the body and
taken up by a wide variety of cells. These
MP and cell interactions, as far as selectivity,
attachment, and fusion, are poorly under-
stood. Bone marrow (BM) progenitors are
recognized  as  frequently  accepting  MPs
from BM and other cell types [63,81]. How-
ever, one study showed that B-cell exosomes
bound abundantly only to follicular dendritic
cells, suggesting that MPs contribute to an
elaborate and selective communication sys-
tem [82]. MPs also have been suggested to
play vital roles in shaping the immune re-
sponse during infections by facilitating co-
agulation and delivering MHC receptors and
CD40L to appropriate cell types [70,83-85].
MPs potentially may serve as a biomarker
for pathogenesis or vaccine effectiveness
[85-88]. Investigations describing MP par-
ticipation during the course of infection can
offer great insight and should be studied fur-
ther.
In humans, the majority of MPs are de-
rived from platelets [69]. Interestingly, DV
can be found in human and monkey platelets
(Figure 1B and C) [57,58], which are shed
from megakaryocytes during differentiation.
These anucleated cells can fragment into
many smaller vesicles, termed platelet-de-
rived particles or “platelet dust” [89-92].
This evidence suggests that there are likely
to be platelet-derived vesicles containing
dengue virus found in vivo. Accordingly,
dengue virus can be easily cultured from
human serum or plasma, which doesn’t con-
tain detectable virions or platelets but does
have platelet-derived MPs. All that can be
found in plasma concentrates from dengue
patients are small cellular vesicles, which
likely contain viral components (Figure 2).
Virus quantity may be too low in these types
of  samples  for  visualization  by  EM,  but
there is an alternative hypothesis to explain
these findings. Dengue virions may resem-
ble the host’s cellular vesicles. 
Testing this hypothesis will be difficult
because the human cell population(s) that
harbor and replicate DV in vivo have not
been determined. The literature suggests that
virus is likely to infect a cell frequently
found in the bone marrow and capable of
differentiating into megakaryocytes, shed-
ding the DV-containing platelets noted in the
literature [58,93]. Additional evidence ac-
quired with platelet progenitor cell lines,
Meg-01 and K562, demonstrates that the
MEP  lineage  is  highly  permissive  for
dengue virus infection (unpublished results
and [3]). With these cell types, even in su-
crose fractions with the highest DV RNA
contents, no classical virions and only host-
derived MPs are readily detectable. Repli-
cation of DV in this lineage in vivo may
explain the inability to find obvious virions
in patient samples and would suggest that
Meg01 and K562 are the most appropriate
for studying human components of the DV
life cycle.
Additionally, encapsidation of multiple
genomes into MPs could partially explain the
difficulty of detecting virions in patient blood
with  high  RNA  copy  numbers.  It  is  well
known that there is a difference between DV
quantified  by  real  time  RT-PCR  and  by
plaque or focus forming unit assays. It is gen-
erally accepted that these assays result in dif-
ferent virus titers because there are higher
levels of RNA than there are infectious virus.
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figure 2. transmission eM of plasma
concentrate pooled from multiple pa-
tients. Plasma was spun with an ultrahigh
speed at130,000xg for 30 minutes, and the
pellets were prepared as described in Fig-
ure 1. Small vesicles containing virus parti-
cles were observed.If instead a single MP packages 10 or more
virus genomes, then this could account for
lower infectious virus quantities. The con-
centration of infectious particles would de-
crease by at least one log and make EM virion
visualization more difficult. Also, this would
skew the infectious virus to defective virus
particle  ratio.  In  DV2-infected  K562  and
Meg01 cells, this ratio spans anywhere from
the upper 100s to lower 10,000s [unpublished
results]. With the MP transmission scenario,
there  could  be  many  functional  genomes
clustered into the same microvesicle but only
one MP and cell fusion event, resulting in one
infectious  focus  unit.  Fusion  of  multiple
genomes or a quasi-species into one cell may
facilitate a more robust and productive infec-
tion. These particles also may shield virus
from immune system components, allowing
for infection in spite of preexisting high neu-
tralizing titers [94]. This may permit the re-
tention of virus in the blood for extensive
periods of time, making possible efficient
transmission to the mosquito vector. 
VectoR-BoRne DISeaSe 
tRanSMISSIon
Dengue is a vector-borne virus that is
contracted through the bite of an infected fe-
male Aedes spp. mosquito. It is often the
case with vector-borne parasites that the in-
fectious agent takes on a different structural
form to accomplish infection in divergent
species. In the case of malaria transmission,
the plasmodium needs to assemble into the
sporozoite in the mosquito salivary gland in
order to be transmitted to and infect humans
[95]. However, the merozoite must be pres-
ent in human blood imbibed by the Anophe-
les spp. mosquito vector to complete the
cycle and be available for future transmis-
sion. Without transmission of the appropri-
ate  form,  the  next  host  organism  cannot
acquire the infection. 
To the best of our knowledge, these
types of polymorphisms have not been noted
with vector-borne viruses. Insect cell DV
progeny have been described with multiple
morphologies: the classic, capsid-less, and
filamentous [35,47]. We have observed a
microparticle-associated VAM, which may
be present in other mammalian cell lines.
However, the physical structure of the virus
in the mosquito saliva acquired during blood
meal from an infected individual has not
been documented. Virus morphology is usu-
ally observed in the gut or salivary glands
after, rather than before, propagation in the
insect vector [96]. The investigations that
have visualized virus entering the proboscis
have infected Aedes with cell culture-de-
rived virus rather than patient blood [97].
This detail may have escaped DV investiga-
tors due to unsuccessful attempts to detect
virus in this substance. It may have been as-
sumed that virus particles were too few and
below detection limits to be visualized by
EM [personal communications, Dr. Duane
Gubler]. Interestingly, it has been known
that dynamic dengue viral particles exist in
vivo, based upon fractionation with sucrose
density gradients [40,42,47]. Therefore, the
lessons learned from parasitology, that in-
fectious agents often morph into other forms
at different stages of their life cycles, may
have been overlooked. VAMs may be pres-
ent in patient blood, potentially required for
productive evasion of the immune system
and transmission to the vector or for specific
host-pathogen interactions. It is not unrea-
sonable to expect that the dengue E-M pro-
tein complex in the classical structure cannot
fuse equally well with receptors on mam-
malian and insect cells. Differential glyco-
sylation  has  already  been  attributed  to
variations in virus titers in insect versus
mammalian cells [32]. We propose that at
least two different forms of DV could be
generated to complete its life cycle in nature:
a classical and a microparticle-associated
form. Both forms would need to be consid-
ered when designing effective vaccines and
drug candidates.
IMplIcatIonS anD cuRRent
Dengue VaccIne effoRtS
Despite more than 60 years of extensive
effort, little progress has been made at de-
veloping effective vaccines to prevent the
occurrence of infection or disease [98]. Sev-
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chimeras, subunit, and plasmid-based DNA
vaccines) have been or are currently being
attempted; most have failed to elicit protec-
tive immunity in children [99-101]. Cur-
rently, there are no approved vaccines, but a
number of candidates are under develop-
ment. The clinical trials evaluating their re-
actogenicity and immunogenicity have not
yet resolved [102]. The furthest along, be-
ginning phase III clinical trials, is the Sanofi
Pasteur dengue vaccine (chimeric yellow
fever backbone-dengue attenuated vaccine,
CYD),  which  contains  four  intra-strain
chimeras that are highly attenuated in hu-
mans and noted for its capacity to elicit neu-
tralizing antibodies [103]. Assuming one of
these candidates is successful at reducing se-
vere disease, it will still be another 5 to 10
years before one of these candidates will
reach the market.
However, a highly protective vaccine
against dengue virus is very unlikely for a
number of reasons. One of the difficulties in
vaccine design has been attributed to dengue
virus genetic diversity. Because there are four
distinct serotypes and sequential infections
with different strains may be a risk factor for
severe manifestations, it is imperative to have
a tetravalent vaccine that can efficiently and
simultaneously prevent disease from all four
viral serotypes. Clinical trial evaluations have
revealed that imbalances and interference in
the  immune  responses  between  the  four
strains in the formulation is a major concern
[98,104]. When infecting with multiple re-
lated viruses, which likely compete with each
other for the same cellular hosts, there is al-
ways a tendency for one of them to dominate
(or out-replicate) the others. This results in an
uneven immune response, eliciting better an-
tibody titers to a few serotypes rather than all
of them. Thus development of a vaccine with
the right combination is critical to achieve a
balanced immune response that does not con-
tribute to immune-mediated dengue disease
(DHF/DSS) in vaccinated individuals [105].
A successful vaccine is also unlikely because
there is no known correlate of protection; the
neutralizing antibody response has not been
proven to predict disease severity [106,107].
Another factor that has contributed to
the slow progress toward an effective vac-
cine is the lack of a suitable disease animal
model. These model systems are integral for
evaluating drug and vaccine candidates and
gaining insight into the molecular mecha-
nisms responsible for clinical presentations.
Since the early 1900s, many attempts to re-
produce the disease in animals have been
conducted. More than 500 species of ani-
mals  have  been  tested  to  date;  however,
none of them were capable of being infected
by dengue virus and displaying the cardinal
features of the disease [108,109]. Dynamic
clinical manifestations of dengue patients,
ranging from dengue fever, DF with abnor-
mal bleeding, DHF, DHF/DSS, to DSS with
complications, have hindered the progress
toward an animal disease model. Although
certain rodent species have been implicated
to display some clinical symptoms, the main
phenotype of the disease is neurovirulence
without bleeding diathesis or plasma leak-
age, which is not characteristic of human ill-
ness  [45,110,111].  In  addition,  virus
propagated in rodents display altered bio-
logical properties since it is attenuated in hu-
mans [45,110,111]. Recently, a humanized
mouse model was developed to determine
its suitability as a dengue disease model
[112-114]. These animals are capable of be-
coming infected with DV as well as dis-
playing  hemorrhages.  Still,  they  do  not
present with other salient human features
such as thrombocytopenia, plasma leakage,
or shock. The immune responses to DV in-
fection in this model have not been studied
in  enough  detail  to  provide  insight  into
dengue disease. Consequently, if they dis-
played symptoms more similar to human
disease in response to dengue virus infec-
tion, rodents would be an ideal small animal
model.
Despite the inadequacies of the rodent
model to study dengue virus pathogenesis,
there is another type of animal model: the
non-human primate [22,115]. It is accepted
that  they  are  a  natural  reservoir  for  this
pathogen in the wild [108]. However, infec-
tions in primate species do not consistently or
as extensively develop the prominent dengue
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have revealed that the levels of NS-1, a non-
structural protein extensively secreted from
infected cells, and viral load, both indicators
of disease severity, are far lower in monkeys
than in humans, potentially explaining their
milder symptoms [115]. Recently, a primate
dengue coagulopathy model was developed
by administration of a high dose of dengue
virus intravenously [22]. Perhaps this model
could be a useful tool to evaluate the efficacy
of future candidate dengue vaccines. 
A common unfortunate finding in live
attenuated vaccine studies is the reoccur-
rence of viremia upon booster shots, regard-
less  of  the  route  of  infection  and  high
neutralizing antibody titers [116,117]. High
viremia in dengue patients with pre-existing
neutralizing antibody also has been docu-
mented, but the mechanism is poorly under-
stood  [94].  Viral  strain  differences,
immune-mediated inhibition, and individual
genetic background, age, and nutritional sta-
tus have all been suggested to be contribut-
ing  factors.  However,  the  problem  with
viremia is dismissed by DV vaccinologists,
who have relaxed their standards for steril-
izing immunity [99]. It is considered ac-
ceptable to get viremia levels of 103 pfu per
ml, because it will theoretically eliminate
transmission [99]. However, this value as-
sumes that infected individuals are bitten
only once by a mosquito during the 3- to 5-
day period of viremia. Unfortunately, with-
out the elimination of blood borne virus,
transmission to mosquitoes cannot be pre-
vented  and  herd  immunity  cannot  be
achieved. If vaccine recipients are still get-
ting an infection and shedding virus into
their circulation, they are still capable of
transmitting to the mosquito and contribut-
ing to the occurrence of outbreaks.
This inability to eliminate viremia may
be due to the lack of an adequate antibody
response to the VAM, or alternatively, it
could be explained by antibody depletion
that occurs sometime after DV infection and
before  hospitalization  [118].  Dengue  pa-
tients that come to the hospital and are diag-
nosed with DF often display low levels of
dengue specific antibody at admission, even
in secondary infections [119]. The mecha-
nism for this inhibition is unknown but is
likely due to the alteration in cellularity of
the bone marrow and the potential death of
the residing plasma cells [57,120]. This dis-
ruption in antibody production is likely re-
quired  for  adequate  human-to-mosquito
transmission. Determining vaccine efficacy
by neutralizing antibody response demon-
strated in vitro, especially with monkey kid-
ney cell lines like Vero, may be inefficient
as an indicator for disease prevention. An-
other approach is needed.
Many formulations have been used in
vaccine  design.  However,  virus  isolated
from MEP cell lines, which assemble an al-
ternative virus form, has not been tested for
its ability to stimulate the immune response
and prevent disease. Heat-killed MP-associ-
ated virus may be a viable candidate to test
in future trials.  
IMplIcatIonS on DRug DeSIgn
Besides preventive vaccines, other med-
ical  interventions  under  development  are
pharmaceuticals that can prevent virus entry
or replication in the host. Drugs blocking
virus uptake is being attempted by many
groups. One difficulty facing this effort is the
uncertainty over the host-pathogen interac-
tions to inhibit. Many host proteins that me-
diate  attachment  to  the  virus  have  been
suggested, but the true receptor(s) responsi-
ble for triggering fusion and entry have yet to
be discovered and agreed upon [54]. There-
fore, the design of small molecule fusion in-
hibitors has been focused against the virus
receptor envelope protein. Molecules may be
designed to fit into the binding pockets ob-
served between envelope and some putative
attachment receptor proteins. Although drug
design can progress without knowing the true
host receptor protein interactions that need to
be blocked, the absence of a suitable animal
model makes drug efficacy difficult to deter-
mine. One potential DV receptor considered
for drug design is the E/DC-SIGN interaction
[121]. Does blocking this interaction prevent
DV infection or inhibit the protective immune
response? Research has indicated the DV E
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on  dendritic  cells;  however,  DC-SIGN  is
present on a high percentage of these cells
while only a small percentage (~2 to 5 per-
cent) of DCs support infection [122,123]. A
drug against DC-SIGN would likely mas-
sively alter downstream signaling in a num-
ber of cells, changing the innate immune
system response, and contributing to toxicity
in the host. Foreseeably, this candidate is
more likely to contribute to immune-medi-
ated disease. Another drug design strategy is
to target the N-octyl-ʲ-D-glucoside molecule,
which should prevent confirmation changes
associated with classical virus maturation and
fusion [54]. Interestingly, there are also anti-
bodies that bind to DV particles better after
hidden epitopes are exposed at higher tem-
peratures, for instance, when shifted from
room temperature to normal body tempera-
ture [34], implicating that the same scenario
could occur under the physiological temper-
ature of fever. Lastly, there are attempts at de-
signing dengue viral drugs that interfere with
dengue virus genome replication [124,125].
No drugs are currently available for thera-
peutic treatment. Very few have been suc-
cessful in animal models [126]. Inhibition of
viral replication is often screened in conven-
ient cell lines and never in more relevant
cells, such as the MEP cell lines or whole
bone marrow, the suggested site for dengue
virus replication in vivo[57,93,127]. Evalua-
tion of dengue virus replication in these cell
types may be a helpful strategy for screening
drug candidates.
As aforementioned, dengue patients gen-
erally do not seek professional help until the
late stage of fever, often after 2 to 3 days of
clinical illness, at which time, the viral load is
either at its peak or progressing downward
[128]. Thus, the severe dengue disease is ob-
served not at the time when the viral burden
is at its highest in vivo, but rather when the
virus is being rapidly cleared from host tis-
sues by the innate and adaptive immune re-
sponses [129]. It is critical to bear in mind
that dengue viral antigen in leukocytes are
most likely seen after the cessation of viremia
[130]. This suggests that the pathogenesis of
clinically important complications is closely
linked  to  the  host  immune  response
[129,131]. However, the underlying mecha-
nisms causing DHF/DSS are in debate. Cur-
rent  evidence  strongly  suggests  that  the
immune response to dengue virus infection,
predominantly inflammatory cytokines in the
serum of patients, plays a key role in the
pathophysiological cascade leading to plasma
leakage and shock [132-139], which presum-
ably results from the action of phagocytosis
[22,140]. Consequently, despite the amount
of work dedicated to dengue drug design tar-
geted on blocking virus replication and entry,
treatments with any of these candidates are
unlikely to work in the clinic. Additionally,
since there is no evidence suggesting that
classical viral particles exist in the human, the
success of this drug design approach is likely
to be low.
The inability to find classical dengue
virions in patient serum or plasma and the
dynamic clinical presentation of illness in
dengue patients [60,111] suggest the pheno-
typic structure of the virus in vivo is likely to
be a versatile VAM. Therefore, targeting im-
mune modulators that work by selectively
blocking mechanisms involved in the in-
flammatory and immune response would be
a way to go for therapeutic drug develop-
ment. Thus, more attention should be spent
on designing immune system modulators
that down-regulate the responses that con-
tribute to vascular permeability and shock.
For chronic infectious diseases, this strategy
is  not  preferred  because  inhibition  often
leads to the unchecked amplification of the
pathogen and increased risk of death in pa-
tients. On the contrary, dengue is an acute
disease. By the time DHF/DSS occurs, the
virus has likely run out of appropriate cellu-
lar hosts. This drug design strategy may be
more safe and feasible with dengue disease
than with other infectious agents that has
been tested in the past [141,142]. 
SuMMaRy anD concluSIon
Dengue virus causes a challenging dis-
ease with diverse and nonspecific symptoms
that are difficult to control. These problems
are amplified by the tendency for patients to
12 Clark et al.: Microparticles in dengue virus infectionseek health care at late stages of infection,
often during the phase of viral clearance.
This review suggests that like other vector-
borne pathogens, dengue virus may also be
able to take on different structural forms, a
classical virion and a VAM, in order to com-
plete its life cycle in different hosts. Investi-
gations using patient plasma and Meg01 and
K562 cell lines have suggested that the DV
genome may be able to be packaged into
host-derived microparticles. An alternative
morphology may allow DV a way to escape
the immune system while in search for its
next host and may also allow for a more ro-
bust infection in the vector. In combination
with other issues such as the absence of a
good animal, the dynamic biological mor-
phology and life cycle of DV may compli-
cate  efforts  to  design  safe  and  effective
vaccines and drugs. This concept needs to be
further and more carefully investigated. Suc-
cessful preventive and therapeutic strategies
are not possible without a more complete un-
derstanding of the DV life cycle.
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